2020

NervGen Pharma Engages CRO for Phase 1 Clinical Trial

NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update

NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer’s Disease Program / NervGen Renews Business Advisory Relationship with Brian McAlister

NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update

NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-dilutive Funding Sources for NVG-291

NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders

NervGen Pharma Announces Annual General Meeting and Company Update to be Held on September 30, 2020

NervGen Pharma Announces Departure of Chief Operating Officer / LifeSci Advisors Engaged to Provide Investor Relations Services

NervGen Pharma Reports Second Quarter 2020 Results / Phase 1 Clinical Study Remains on Track for Q4 2020